|Table of Contents|

Research progress on the application of thyroglobulin antibody(TgAb) in the clinical diagnosis of differentiated thyroid carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 17
Page:
3330-3334
Research Field:
Publishing date:

Info

Title:
Research progress on the application of thyroglobulin antibody(TgAb) in the clinical diagnosis of differentiated thyroid carcinoma
Author(s):
KANG Dou; ZHAO Changjiu
The First Affiliated Hospital of Harbin Medical University,Heilongjiang Harbin 150001,China.
Keywords:
differentiated thyroid carcinoma; thyroglobulin; iodine-131; thyroglobulin antibody
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2023.17.035
Abstract:
Thyroid cancer is the most common malignant tumor in the endocrine system.In recent years,the incidence of thyroid cancer has been increasing continuously,and has become the fastest growing malignant tumor in the world for women.Differentiated thyroid carcinoma(DTC) is the most common types of thyroid cancer.Thyroglobulin(Tg) is a serum tumor marker that monitors metastasis or recurrence after DTC surgery and iodine-131(131I ) treatment.Thyroglobulin antibody(TgAb)a conventional thyroid autoimmune marker,is commonly seen in chronic lymphocytic thyroiditis.Some scholars believe that elevated TgAb level is closely related to the increased risk of thyroid nodules,and is an independent risk factor for DTC.Positive TgAb in DTC patients interferes with the detection of Tg,thus limiting the role of Tg in the monitoring of DTC patients.At present,most scholars in the world believe that TgAb level can be used as a substitute tumor marker for DTC when serum Tg measurement is disturbed by the presence of TgAb.Postoperative TgAb level in DTC patients not only has a certain predictive value in DTC metastasis,but also can be evaluated after taking 131I to clear the curative effect.In addition,increased TgAb levels were associated with the risk of DTC recurrence during post-DTC follow-up.Therefore,this paper summarized the research progress of TgAb in the clinical application of DTC to provide more basis for the clinical decision-making of TgAb positive patients.

References:

［1］ZHANG X,ZHANG X,CHANG Z,et al.Correlation analyses of thyroid-stimulating hormone and thyroid autoantibodies with differentiated thyroid cancer［J］.J Buon,2018,23(5):1467-1471.
［2］RITTER A,MIZRACHI A,BACHAR G,et al.Detecting recurrence following lobectomy for thyroid cancer:role of thyroglobulin and thyroglobulin antibodies［J］.J Clin Endocrinol Metab,2020,105(6):dgaa152.
［3］ CHAI J,ZHANG R,ZHENG W,et al.Predictive value of clinical and pathological characteristics for metastatic radioactive iodine-refractory differentiated thyroid carcinoma:A 16-year retrospective study［J］.Front Endocrinol Lausanne,2022,13:930180.
［4］KIM JW,ROH JL,GONG G,et al.Treatment outcomes and risk factors for recurrence after definitive surgery of locally invasive well-differentiated papillary thyroid carcinoma［J］.Thyroid,2016,26(2):262-270.
［5］ XI C,ZHANG GQ,SONG HJ,et al.Change in antithyroglobulin antibody levels is a good predictor of responses to therapy in antithyroglobulin antibody-positive pediatric papillary thyroid carcinoma patients［J］.Int J Endocrinol,2022,2022:7173919.
［6］HAUGEN BR,ALEXANDER EK,BIBLE KC,et al.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］.Thyroid,2016,26(1):1-133.
［7］TOZZOLI R,BIZZARO N.Harmonization in autoimmune thyroid disease diagnostics［J］.Clin Chem Lab Med,2018,56(10):1778-1782.
［8］SPENCER C.Commentary on:Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer:a clinical position statement［J］.Thyroid,2013,23(10):1190-1192.
［9］ 周琼,陈森良,罗淼,等.血清Tg和TgAb水平监测在分化型甲状腺癌患者131I清甲治疗中的临床意义［J］.中国医学前沿杂志(电子版),2017,9(09):105-108. ZHOU Q,CHEN SL,LUO M,et al.Clinical significance of monitoring serum Tg and TgAb levels in patients with differentiated thyroid cancer treated with 131I nail removal ［J］.Chinese Journal of Frontier Medicine(Electronic Edition),2017,9(09):105-108.
［10］杨晓明,张雪辉,陆名义,等.甲状腺癌131I清甲治疗前后Tg及TgAb测定值分析［J］.肿瘤学杂志,2017,23(04):286-289. YANG XM,ZHANG XH,LU MY,et al.Analysis of Tg and TgAb before and after 131I thyroidectomy ［J］.Journal of Oncology,2017,23(04):286-289.
［11］ FRHLICH E,WAHL R.Thyroid autoimmunity:role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases［J］.Front Immunol,2017,8:521.
［12］VERBURG FA,LUSTER M,CUPINI C,et al.Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer:a clinical position statement［J］.Thyroid,2013,23(10):1211-1225.
［13］LATROFA F,RICCI D,MONTANELLI L,et al.Thyroglobulin autoantibodies in patients with papillary thyroid carcinoma:comparison of different assays and evaluation of causes of discrepancies［J］.J Clin Endocrinol Metab,2012,97(11):3974-3982.
［14］GIOVANELLA L,FELDT-RASMUSSEN U,VERBURG FA,et al.Thyroglobulin measurement by highly sensitive assays:focus on laboratory challenges［J］.Clin Chem Lab Med,2015,53(9):1301-1314.
［15］HAUGEN BR.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:what is new and what has changed［J］.Cancer,2017,123(3):372-381.
［16］GRGES R,MANIECKI M,JENTZEN W,et al.Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy［J］.Eur J Endocrinol,2005,153(1):49-55.
［17］ 韩娜,刘新峰,司增梅,等.分化型甲状腺癌131I治疗后TgAb由阳转阴时间与临床转归的关系 ［J］.国际放射医学核医学杂志,2022,46(7):412-418. HAN N,LIU XF,SI ZM,et al.The relationship between the time of TgAb conversion from positive to negative and clinical outcome after 131I treatment in differentiated thyroid cancer ［J］. International Journal of Radiology and Nuclear Medicine,2022,46(7):412-418.
［18］丛慧,梁军,李方,等.分化型甲状腺癌治疗后TgAb变化趋势及其影响因素［J］.中国医学科学院学报,2015,37(01):61-65. CONG H,LIANG J,LI F,et al.Changes of TgAb after treatment of differentiated thyroid cancer and its influencing factors ［J］.Journal of Chinese Academy of Medical Sciences,2015,37(01):61-65.
［19］ 张娜,林岩松,梁军.甲状腺球蛋白抗体测定在分化型甲状腺癌131I治疗中的临床意义［J］.中国癌症杂志,2019,29(06):452-456. ZHANG N,LIN YS,LIANG J.Clinical significance of thyroglobulin antibody detection in 131I treatment of differentiated thyroid cancer ［J］.China Oncology,2019,29(06):452-456.
［20］HOSSEINI S,PAYNE RJ,ZAWAWI F,et al.Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer［J］.J Otolaryngol Head Neck Surg,2016,45(1):31.
［21］KIM ES,LIM DJ,BAEK KH,et al.Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules［J］.Thyroid,2010,20(8):885-891.
［22］BARIC A,BRCIC L,GRACAN S,et al.Thyroglobulin antibodies are associated with symptom burden in patients with hashimoto's thyroiditis:a cross-sectional study［J］.Immunol Invest,2019,48(2):198-209.
［23］LATINA A,GULLO D,TRIMARCHI F,et al.Hashimoto's thyroiditis:similar and dissimilar characteristics in neighboring areas.Possible implications for the epidemiology of thyroid cancer［J］.PLoS One,2013,8(3):e55450.
［24］LEE JH,KIM Y,CHOI JW,et al.The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis:a meta-analysis［J］.Eur J Endocrinol,2013,168(3):343-349.
［25］NOURELDINE SI,TUFANO RP.Association of Hashimoto's thyroiditis and thyroid cancer［J］.Curr Opin Oncol,2015,27(1):21-25.
［26］WEN X,WANG B,JIN Q,et al.Thyroid antibody status is associated with central lymph node metastases in papillary thyroid carcinoma patients with hashimoto's thyroiditis［J］.Ann Surg Oncol,2019,26(6):1751-1758.
［27］SPENCER CA.Clinical review:Clinical utility of thyroglobulin antibody(TgAb) measurements for patients with differentiated thyroid cancers(DTC)［J］.J Clin Endocrinol Metab,2011,96(12):3615-3627.
［28］TSUSHIMA Y,MIYAUCHI A,ITO Y,et al.Prognostic significance of changes in serum thyroglobulin antibody levels of pre-and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients［J］.Endocr J,2013,60(7):871-876.
［29］JO K,KIM MH,HA J,et al.Prognostic value of preoperative anti-thyroglobulin antibody in differentiated thyroid cancer［J］.Clin Endocrinol(Oxf),2017,87(3):292-299.
［30］VASILEIADIS I,BOUTZIOS G,CHARITOUDIS G,et al.Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma［J］.Ann Surg Oncol,2014,21(8):2725-2732.
［31］DURANTE C,TOGNINI S,MONTESANO T,et al.Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating anti-thyroglobulin autoantibodies［J］.Thyroid,2014,24(7):1139-1145.
［32］ 刘俊朋,高艳山.TAM对TgAb阳性分化型甲状腺癌远处转移的预测价值［J］.重庆医学,2022,51(5):838-841. LIU JP,GAO YS.Predictive value of TAM for distant metastasis of TgAb positive differentiated thyroid carcinoma ［J］. Chongqing Medical Journal,2022,51(5):838-841.
［33］CHUNG JK,PARK YJ,KIM TY,et al.Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation［J］.Clin Endocrinol(Oxf),2002,57(2):215-221.
［34］ 李田军,林岩松,梁军,等.甲状腺球蛋白抗体在甲状腺乳头状癌131I治疗后的转阴时间及其影响因素［J］.中国医学科学院学报,2012,34(03):258-261. LI TJ,LING YS,LIANG J,et al.The time of turning negative after treatment with thyroglobulin antibody in thyroid papillary carcinoma 131I and its influencing factors ［J］.Journal of Chinese Academy of Medical Sciences,2012,34(03):258-261.
［35］ 白亚楠,朱德苑,刘元奎,等.治疗前血清Tg、TgAb、VEGF、MIP-1α对分化型甲状腺癌术后患者首次131I清甲治疗效果的影响［J］.现代生物医学进展,2023,23(2):361-366. BAI YN,ZHU DY,LIU YK，et al.Serum Tg,TgAb,VEGF,MIP-1 before treatment α The effect of the first 131I treatment on postoperative patients with differentiated thyroid cancer ［J］.Progress in Modern Biomedical Sciences,2023,23(2):361-366.
［36］田军军,陶然,沈银峰,等.甲状腺癌患者血清甲状腺球蛋白以及抗甲状腺球蛋白抗体水平与肺转移、骨转移的相关性研究［J］.海南医学院学报,2017,23(12):1679-1681,1685. TIAN JJ,TAO R,SHEN YF,et al.Correlation between serum thyroglobulin and anti-thyroglobulin antibody levels and lung and bone metastasis in patients with thyroid cancer ［J］.Journal of Hainan Medical College,2017,23(12):1679-1681,1685.
［37］ MCLEOD DONALD SA,COOPER DAVID S,LADENSON PAUL W,et al.Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis［J］.Thyroid,2014,24(1):35-42.
［38］ JIA Q,MENG Z,XU K,et al.Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody［J］.Sci Rep,2017,7:43516.
［39］ 刘日信，曾凤伟，李建芳，等.分化型甲状腺癌131I治疗后早期TgAb变化幅度与疗效的关系［J］.临床与病理杂志,2019,39(06):1215-1219. LIU RX,ZENG FW,LI JF,et al.The relationship between the change amplitude of TgAb and curative effect in early stage of differentiated thyroid carcinoma after 131I treatment ［J］.J Clinicopathology,2019,39(06):1215-1219.
［40］张娜,梁军,林岩松.甲状腺球蛋白抗体对甲状腺乳头状癌131I清甲疗效的影响［J］.中国癌症杂志,2017,27(06):476-481. ZHANG N,LIANG J,LING YS.Effect of thyroglobulin antibody on 131I thyroidectomy for papillary thyroid carcinoma ［J］.China Oncology,2017,27(06):476-481.
［41］ 巴雅,祖拉亚提·库尔班,娜姿·依力哈木,等.血清Tg和TgAb对分化型甲状腺癌切除术后131I治疗患者预后的预测价值［J］.疑难病杂志,2023,22(02):144-148+154. BA Y,ZU LYT,NA Z,et al.The predictive value of serum Tg and TgAb for prognosis in patients with differentiated thyroid cancer undergoing 131I treatment after resection ［J］.Journal of Difficult Diseases,2023,22(02):144-148+154
［42］ERNAGA-LOREA A,HERNNDEZ-MORHAIN MC,ANDA-APINIZ E,et al.Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma［J］.Clin Transl Oncol,2018,20(6):740-744.
［43］XIAO Y,ZHOU Q,XU Y,et al.Positive thyroid antibodies and risk of thyroid cancer:A systematic review and meta-analysis［J］.Mol Clin Oncol,2019,11(3):234-242.
［44］TRIMBOLI P,ZILIOLI V,IMPERIALI M,et al.Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome［J］.Clin Chem Lab Med,2017,55(12):1995-2001.
［45］MORBELLI S,FERRARAZZO G,POMPOSELLI E,et al.Relationship between circulating anti-thyroglobulin antibodies(TgAb) and tumor metabolism in patients with differentiated thyroid cancer(DTC):prognostic implications［J］.J Endocrinol Invest,2017,40(4):417-424.

Memo

Memo:
-
Last Update: 2023-07-31